Cited by 915Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 216 of the 218 references it cites were found in a registry or an index.

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Open access

Azzoli, Christopher G., Baker, Sherman, Temin, Sarah, Pao, William, Aliff, Timothy, Brahmer, Julie, Johnson, David H., Laskin, Janessa L., Masters, Gregory, Milton, Daniel, Nordquist, Luke, Pfister, David G., Piantadosi, Steven, Schiller, Joan H., Smith, Reily, Smith, Thomas J., Strawn, John R., Trent, David, Giaccone, Giuseppe·2009·Journal of Clinical Oncology

DOI 10.1200/jco.2009.23.5622PMC PMC2793036

Open this paper in CoChat — free account

Abstract

The purpose of this article is to provide updated recommendations for the treatment of patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. The scope of the guideline was narrowed to chemotherapy and biologic therapy. An Update Committee reviewed the literature and made updated recommendations. One hundred sixty-two publications met the inclusion criteria. Recommendations were based on treatment strategies that improve overall survival. Treatments that improve only progression-free survival prompted scrutiny of toxicity and quality of life. For first-line therapy in patients with performance status of 0 or 1, a platinum-based two-drug combination of cytotoxic drugs is recommended. Nonplatinum cytotoxic doublets are acceptable for patients with contraindications to platinum therapy. For patients with performance status of 2, a single cytotoxic drug is sufficient. Stop first-line cytotoxic chemotherapy at disease progression or after four cycles in patients who are not responding to treatment. Stop two-drug cytotoxic chemotherapy at six cycles even in patients who are responding to therapy. The first-line use of gefitinib may be recommended for patients with known epidermal growth factor receptor (EGFR) mutation; for negative or unknown EGFR mutation status, cytotoxic chemotherapy is preferred. Bevacizumab is recommended with carboplatin-paclitaxel, except for patients with certain clinical characteristics. Cetuximab is recommended with cisplatin-vinorelbine for patients with EGFR-positive tumors by immunohistochemistry. Docetaxel, erlotinib, gefitinib, or pemetrexed is recommended as second-line therapy. Erlotinib is recommended as third-line therapy for patients who have not received prior erlotinib or gefitinib. Data are insufficient to recommend the routine third-line use of cytotoxic drugs. Data are insufficient to recommend routine use of molecular markers to select chemotherapy.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1200/jco.2009.23.5622

Cites

216 of 216 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Self-citation
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
Pao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citation
COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
Chiller, J. O. H. S., Arrington, D. A. H., Elani, C. H. P. B., Anger, C., Andler, A. L. S., Rook, J. A. K., Hu, J., & Ohnson, D. A. H. J. (2002) · Cited by 3,730
The IASLC Lung Cancer Staging Project: Proposals for the Revision of the TNM Stage Groupings in the Forthcoming (Seventh) Edition of the TNM Classification of Malignant Tumours
Goldstraw, P., Crowley, J., Chansky, K., Giroux, D. J., Groome, P. A., Rami-Porta, R., Postmus, P. E., Rusch, V., & Sobin, L. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31812f3c1a · Cited by 3,655

Show all 218 references

Research works printed but not linked: 7

10.1200/jco.2002.20.5.1335 · DOI
Lynch TJ, Presented at the 12th World Conference on Lung Cancer
Lord RV, 2002, Clin Cancer Res, 8, 2286
Mihaylova Z, 2007, J BUON, 12, 105
Langer CJ, 2004, Oncology, 18, 17
Brose MS, 2002, Cancer Res, 62, 6997
Suzuki Y, 1990, Oncogene, 5, 1037

Sorted by citations

Items 401–500 of 911

Lung Cancer in Developing Countries: Access to Molecular Testing
Ferreira, C. G. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.327 · Cited by 20
Methylenetetrahydrofolate reductase C677T polymorphism predicts response and time to progression to gemcitabine-based chemotherapy for advanced non-small cell lung cancer in a Chinese Han population
Hong, W., Wang, K., Zhang, Y., Kou, J., Hong, D., Su, D., Mao, W., Yu, X., Xie, F., & Wang, X. (2013) · Journal of Zhejiang University SCIENCE B · doi:10.1631/jzus.b1200101 · Cited by 19
Treatment Patterns for Advanced Non–Small-cell Lung Cancer After Platinum-containing Therapy in U.S. Community Oncology Clinical Practice
McKay, C., Burke, T. A., Cao, X., Abernethy, A. P., & Carbone, D. P. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.03.008 · Cited by 19
The value of desmosomal plaque-related markers to distinguish squamous cell carcinoma and adenocarcinoma of the lung
Galindo, I., Gómez‐Morales, M., Díaz-Cano, I., Andrades, Á., Molina, M. C., León, M. T. M., Medina, P. P., Martín-Padrón, J., & Fárez‐Vidal, M. E. (2019) · Upsala Journal of Medical Sciences · doi:10.1080/03009734.2019.1692101 · Cited by 19
Rates of guideline adherence among US community oncologists treating NSCLC.
Wang, Z., Askamit, I., Tuscher, L., & Bergstrom, K. (2013) · PubMed · Cited by 19
Definitive dose thoracic radiation therapy in oligometastatic non-small cell lung cancer: A hypothesis-generating study
Xanthopoulos, E. P., Handorf, E. R., Simone, C. B., Grover, S., Fernandes, A., Sharma, S., Corradetti, M. N., Evans, T. L., Langer, C. J., Mitra, N., et al. (2015) · Practical Radiation Oncology · doi:10.1016/j.prro.2014.11.006 · Cited by 20
Strategies for maintenance therapy in advanced non-small cell lung cancer: Current status, unanswered questions and future directions
Custodio, A., & de Castro, J. (2011) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2011.08.003 · Cited by 19
Personalized medicine for non-small-cell lung cancer
Mok, T. S. K., Zhou, Q. H., Leung, L. K. S., & Loong, H. H.-F. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.76 · Cited by 19
A phase II, open-label trial of bortezomib (VELCADE®) in combination with gemcitabine and cisplatin in patients with locally advanced or metastatic non-small cell lung cancer
Kontopodis, E., Kotsakis, A. P., Kentepozidis, N. K., Syrigos, K. N., Ziras, N., Moutsos, M., Filippa, G., Mala, A., Vamvakas, L., Mavroudis, D., et al. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-2997-7 · Cited by 19
Dianhydrogalactitol induces replication-dependent DNA damage in tumor cells preferentially resolved by homologous recombination
Zhai, B., Steinø, A., Bacha, J., Brown, D., & Daugaard, M. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1069-9 · Cited by 19
Clinical models and biochemical predictors of VTE in lung cancer
Roselli, M., Riondino, S., Mariotti, S., Farina, F., Ferroni, P., & Guadagni, F. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9500-x · Cited by 20
Phase II Study of Topotecan and Bevacizumab in Advanced, Refractory Non–Small-Cell Lung Cancer
Powell, S. F., Beitinjaneh, A., Tessema, M., Bliss, R., Kratzke, R. A., Leach, J. W., & Dudek, A. Z. (2013) · Clinical Lung Cancer · doi:10.1016/j.cllc.2013.04.009 · Cited by 19
Advanced non-small cell lung cancer: on relapse rechallenge the tumor, not the patient
Froudarakis, Μ. E., & Briasoulis, E. C. (2010) · BMC Research Notes · doi:10.1186/1756-0500-3-195 · Cited by 18
Influence of histology and biomarkers on first-line treatment of advanced non-small cell lung cancer in routine care setting: Baseline results of an observational study (FRAME)
Schnabel, P. A., Smit, E. F., de Castro, J., Leniewski-Kmak, K., Aerts, J. G. J. V., Kraaij, K., Visseren‐Grul, C., Dyachkova, Y., Taipale, K., Girvan, A. C., et al. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.09.001 · Cited by 18
Chemotherapy and Targeted Therapeutics as Maintenance of Response in Advanced Non-Small Cell Lung Cancer
Johnson, M. L., & Patel, J. D. (2013) · Seminars in Oncology · doi:10.1053/j.seminoncol.2013.12.007 · Cited by 18
Lung Cancer Working Group Report
Saijo, N., Fukuoka, M., Thongprasert, S., Ichinose, Y., Mitsudomi, T., Mok, T. S. K., Ohe, Y., Park, K., & Wu, Y.-L. L. C. (2010) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyq121 · Cited by 18
Adherence to AIOM (Italian Association of Medical Oncology) lung cancer guidelines in Italian clinical practice: Results from the RIGHT-3 (research for the identification of the most effective and highly accepted clinical guidelines for cancer treatment) study
Barni, S., Maiello, E., Maïo, M. D., Ardizzoni, A., Cappuzzo, F., Maranzano, E., Novello, S., Bennati, C., Ori, A., Rizzoli, S., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.005 · Cited by 18
The survival outcomes and prognosis of stage IV non-small-cell lung cancer treated with thoracic three-dimensional radiotherapy combined with chemotherapy
Su, S., Hu, Y., Ouyang, W., Ma, Z., Lü, B., Li, Q., Li, H., Wang, Z., & Wang, Y. (2014) · Radiation Oncology · doi:10.1186/s13014-014-0290-7 · Cited by 18
Effect of DR4 promoter methylation on the TRAIL-induced apoptosis in lung squamous carcinoma cell
Wang, W., QI, X., & Wu, M. (2015) · Oncology Reports · doi:10.3892/or.2015.4170 · Cited by 18
Cisplatin and carboplatin-based chemotherapy in the first-line treatment of non-small cell lung cancer: Analysis from the European FRAME study
Smit, E. F., Moro‐Sibilot, D., de Castro, J., Leśniewski-Kmak, K., Aerts, J. G. J. V., Villatoro, R., Kraaij, K., Nacerddine, K., Dyachkova, Y., Smith, K. T., et al. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.11.022 · Cited by 18
A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician’s choice in patients with advanced non-small cell lung cancer
Katakami, N., Felip, E., Spigel, D. R., Kim, J. H., Olivo, M. S., Guo, M., Nokihara, H., Yang, J. C., Iannotti, N. O., Satouchi, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx284 · Cited by 18
Third-line or fourth-line chemotherapy in non-small-cell lung cancer patients with relatively good performance status
Chen, Y.-M., Shih, J.-F., Fan, W.-C., Wu, C.-H., Chou, K., Tsai, C., Lee, Y.-C., Perng, R.-P., & Whang‐Peng, J. (2011) · Journal of the Chinese Medical Association · doi:10.1016/j.jcma.2011.03.005 · Cited by 18
Ligand-conjugated pH-sensitive polymeric micelles for the targeted delivery of gefitinib in lung cancers
Wang, S., Huo, Z., Liu, K., Yu, N., Ma, Y., Qin, Y., Li, X., Yu, J., & Wang, Z. (2015) · RSC Advances · doi:10.1039/c5ra09931e · Cited by 17
Maintenance chemotherapy for non-small-cell lung cancer
Kim, Y. H., & Mishima, M. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2010.12.007 · Cited by 17
Third- and Further-Line Therapy in Advanced Non-Small-Cell Lung Cancer Patients: an Overview
Genestreti, G., Grossi, F., Genova, C., Burgio, M. A., Bongiovanni, A., Gavelli, G., Bartolotti, M., Battista, M. D., Cavallo, G., & Brandes, A. A. (2014) · Future Oncology · doi:10.2217/fon.14.96 · Cited by 17
Usefulness of nanofluidic digital PCR arrays to quantify T790M mutation in EGFR-mutant lung adenocarcinoma.
Isobe, K., Hata, Y., Tochigi, N., Kaburaki, K., Kobayashi, H., Makino, T., Otsuka, H., Ishida, F., Hirota, N., Sano, G., et al. (2015) · PubMed · Cited by 17
Bayesian network meta-comparison of maintenance treatments for stage IIIb/IV non-small-cell lung cancer (NSCLC) patients with good performance status not progressing after first-line induction chemotherapy: Results by performance status, EGFR mutation, histology and response to previous induction
Tan, P. S., Lopes, G. D. L., Jr., Acharyya, S., Bilger, M., & Haaland, B. A. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.07.007 · Cited by 18
Phase II study of carboplatin and pemetrexed in advanced non-squamous, non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0902
Kim, Y. H., Hirabayashi, M., Togashi, Y., Hirano, K., Tomii, K., Masago, K., Kaneda, T., Yoshimatsu, H., Otsuka, K., Mio, T., et al. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1910-2 · Cited by 17
Visualization of rodent brain tumor angiogenesis and effects of antiangiogenic treatment using 3D ΔR2-μMRA
Lin, C.-Y. E., Siow, T. Y., Lin, M.-H., Hsu, Y.-H., Tung, Y.-Y., Jang, T., Recht, L. D., & Chang, C. (2013) · Angiogenesis · doi:10.1007/s10456-013-9355-8 · Cited by 17
Second-line therapy for NSCLC in clinical practice: baseline results of the European SELECTTION observational study
Moro‐Sibilot, D., Vergnenégre, A., Smit, E. F., Toy, E., Parente, B., Schmitz, S. H., Kraaij, K., Visseren‐Grul, C., Soldatenkova, V., Arellano, J., et al. (2010) · Current Medical Research and Opinion · doi:10.1185/03007995.2010.525489 · Cited by 17
ΔNp63, CK5/6, TTF-1 and napsin A, a reliable panel to subtype non-small cell lung cancer in biopsy specimens.
Zhao, W., Wang, H., Peng, Y. S., Tian, B., Peng, L., & Zhang, D. (2014) · PubMed Central · Cited by 17
Knockdown of Cul4A increases chemosensitivity to gemcitabine through upregulation of TGFBI in lung cancer cells
Hung, M., Chen, I., You, L., Jablons, D. M., Li, Y., Mao, J., Xu, Z., Hsieh, M., LIN, Y.-C., Yang, C., et al. (2015) · Oncology Reports · doi:10.3892/or.2015.4324 · Cited by 17
Patients With Advanced Non–Small-Cell Lung Cancer and Marginal Performance Status: Walking the Tight Rope Towards Improved Survival
West, H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.1502 · Cited by 17
Elevated serum levels of vascular endothelial growth factor predict a poor prognosis of platinum-based chemotherapy in non-small cell lung cancer
Zang, J., Hu, Y., Xu, X., Ni, J., Yan, D., Liu, S., He, J., Xue, J., Wu, J., & Feng, J. (2017) · OncoTargets and Therapy · doi:10.2147/ott.s124124 · Cited by 17
Immunotherapy in treatment naïve advanced non-small cell lung cancer
Ernani, V., & Ganti, A. K. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.94 · Cited by 19
Patient outcomes post-pulmonary resection for synchronous bone-metastatic non-small cell lung cancer
Takahashi, Y., Adachi, H., Mizukami, Y., Yokouchi, H., Oizumi, S., & Watanabe, A. (2019) · Journal of Thoracic Disease · doi:10.21037/jtd.2019.09.17 · Cited by 16
Sequential Treatment with an Immune Checkpoint Inhibitor Followed by a Small-Molecule Targeted Agent Increases Drug-Induced Pneumonitis
Jung, J., Kim, H. Y., Kim, D., Park, S. Y., Ko, A. R., Han, J., Kim, H. T., Lee, J. S., & Lee, Y. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2020.543 · Cited by 17
Analysis of advanced lung cancer patients diagnosed following emergency admission
Fujimoto, D., Shimizu, R., Morimoto, T., Kato, R., Sato, Y., Kogo, M., Ito, J., Teraoka, S., Otoshi, T., Nagata, K., et al. (2014) · European Respiratory Journal · doi:10.1183/09031936.00068114 · Cited by 17
Functional profiling to select chemotherapy in untreated, advanced or metastatic non-small cell lung cancer.
Nagourney, R. A., Blitzer, J. B., Shuman, R. L., Asciuto, T., Deo, E. A., Paulsen, M., Newcomb, R. L., & Evans, S. S. (2012) · PubMed · Cited by 17
Oxaliplatin-Based Doublets Versus Cisplatin or Carboplatin-Based Doublets in the First-Line Treatment of Advanced Nonsmall Cell Lung Cancer
Yu, J., Xiao, J., Yang, Y., & Cao, B. (2015) · Medicine · doi:10.1097/md.0000000000001072 · Cited by 17
Effectiveness of palliative care for non-small cell lung cancer
Li, H., & Li, J. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3621 · Cited by 17
PARAMOUNT: Descriptive Subgroup Analyses of Final Overall Survival for the Phase III Study of Maintenance Pemetrexed versus Placebo Following Induction Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
Reck, M., Paz-Ares, L. G., de Marinis, F., Molinier, O., Sahoo, T. P., Laack, E., John, W. J., Zimmermann, A. H., Visseren‐Grul, C., & Gridelli, C. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000076 · Cited by 16
Management of NSCLC Disease Progression After First-Line EGFR Tyrosine Kinase Inhibitors: What Are the Issues and Potential Therapies?
Califano, R., Romanidou, O., Mountzios, G., Landi, L. M., Cappuzzo, F., & Blackhall, F. H. (2016) · Drugs · doi:10.1007/s40265-016-0578-z · Cited by 16
Design, Synthesis, and Biological Evaluation of Indole-2-carboxamides as Potential Multi-Target Antiproliferative Agents
Al-Wahaibi, L. H., Mohammed, A. F., Abdelrahman, M. H., Trembleau, L., & Youssif, B. G. M. (2023) · Pharmaceuticals · doi:10.3390/ph16071039 · Cited by 16
Optimal Pharmacotherapeutic Strategies for Elderly Patients with Advanced Non-Small Cell Lung Cancer
Quoix, É. (2011) · Drugs & Aging · doi:10.2165/11595100-000000000-00000 · Cited by 16
Phase II Study of Erlotinib as Third-line Monotherapy in Patients with Advanced Non-small-cell Lung Cancer without Epidermal Growth Factor Receptor Mutations
Matsuura, S., Inui, N., Ozawa, Y., Nakamura, Y., Toyoshima, M., Yasuda, K., Yamada, T., Shirai, T., Suganuma, H., Yokomura, K., et al. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr079 · Cited by 16
Epidermal Growth Factor Receptor Mutation and Anaplastic Lymphoma Kinase Gene Fusion: Detection in Malignant Pleural Effusion by RNA or PNA Analysis
Chen, Y.-L., Lee, C., Lu, C.-C., Yang, S.-C., Chen, W.-L., Lee, Y.-C., Yang, C.-H., Peng, S.-L., Su, W., Chow, N.-H., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0158125 · Cited by 16
Pharmacokinetic/pharmacodynamic modeling of combination-chemotherapy for lung cancer
Curtis, L. T., van Berkel, V. H., & Frieboes, H. B. (2018) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2018.03.035 · Cited by 16
Advanced Non-Small Cell Lung Cancer with Activating Epidermal Growth Factor Receptor Mutation: First Line Treatment and Beyond
Rocco, D., Battiloro, C., Gravara, L. D., & Gridelli, C. (2018) · Reviews on Recent Clinical Trials · doi:10.2174/1574887114666181205155211 · Cited by 16
Oral maintenance metronomic vinorelbine versus best supportive care in advanced non-small-cell lung cancer after platinum-based chemotherapy: The MA.NI.LA. multicenter, randomized, controlled, phase II trial
Platania, M., Pasini, F., Porcu, L., Boeri, M., Verderame, F., Modena, Y., Conte, A. D., Nichetti, F., Garassino, M. C., Martinetti, A., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.04.001 · Cited by 16
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
Лактионов, К. К., Артамонова, Е. В., Borisova, T. N., Владимирович, Б. В., Маркович, Б. Ю., Vladimirova, L. Y., Volkov, N., Ергнян, С. М., Zhabina, A. S., Kononets, P. V., et al. (2021) · Journal of Modern Oncology · doi:10.26442/18151434.2021.3.201048 · Cited by 19
Cisplatin, fotemustine and whole-brain radiotherapy in non-small cell lung cancer patients with asymptomatic brain metastases: A multicenter phase II study of the Gruppo Oncologico Italia Meridionale (GOIM 2603)
Galetta, D., Gebbia, V., Silvestris, N., Ferraù, F., Carrozza, F., Cigolari, S., Russo, P., Calista, F., Adamo, V., & Colucci, G. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.07.013 · Cited by 16
Inhibition of homologous recombination with vorinostat synergistically enhances ganciclovir cytotoxicity
Ladd, B., Ackroyd, J. J., Hicks, J. K., Canman, C. E., Flanagan, S. A., & Shewach, D. S. (2013) · DNA repair · doi:10.1016/j.dnarep.2013.10.008 · Cited by 16
Radiation dose and survival of patients with stage IV non-small cell lung cancer undergoing concurrent chemotherapy and thoracic three-dimensional radiotherapy: reanalysis of the findings of a single-center prospective study
Ouyang, W., Su, S., Hu, Y., Lü, B., Ma, Z., Li, Q., Li, H., & Geng, Y. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-491 · Cited by 16
Randomized Phase II Study of Pemetrexed Versus Gefitinib in Previously Treated Patients with Advanced Non-small Cell Lung Cancer
Kim, Y. S., Cho, E. K., Woo, H. S., Hong, J., Ahn, H. K., Park, I., Sym, S. J., Kyung, S. Y., Kang, S. M., Park, J.-W., et al. (2015) · Cancer Research and Treatment · doi:10.4143/crt.2014.307 · Cited by 16
Gefitinib versus docetaxel in previously treated advanced non-small-cell lung cancer: A meta-analysis of randomized controlled trials
Jiang, J., Huang, L., Liang, X., Zhou, X., Huang, R., Chu, Z., & Zhan, Q. (2010) · Acta Oncologica · doi:10.3109/0284186x.2010.546368 · Cited by 16
Rescue Surgery after Immunotherapy/Tyrosine Kinase Inhibitors for Initially Unresectable Lung Cancer
Galetta, D., de Marinis, F., & Spaggiari, L. (2022) · Cancers · doi:10.3390/cancers14112661 · Cited by 15
The Qualification of Docetaxel or Erlotinib for Second-Line Therapy Should Be Based on Clinical and Molecular Predictive Factors
Krawczyk, P. A., Kowalski, D. M., Wojas‐Krawczyk, K., Mlak, R., Jaśkiewicz, P., Kucharczyk, T., Winiarczyk, K., Krzakowski, M. J., & Milanowski, J. (2012) · Chemotherapy · doi:10.1159/000336143 · Cited by 15
Phase II study of pemetrexed as first-line treatment in elderly (≥75) non-squamous non-small-cell lung cancer: Kyoto Thoracic Oncology Research Group Trial 0901
Kim, Y. H., Hirabayashi, M., Kosaka, S., Nikaidoh, J., Yamamoto, Y., Shimada, M., Toyazaki, T., Nagai, H., Sakamori, Y., & Mishima, M. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2142-9 · Cited by 15
Prognostic score for second-line chemotherapy of advanced non-small-cell lung cancer: External validation in a phase III trial comparing vinflunine with docetaxel
Maïo, M. D., Krzakowski, M. J., Fougeray, R., Kowalski, D. M., & Gridelli, C. (2012) · Lung Cancer · doi:10.1016/j.lungcan.2012.01.013 · Cited by 15
Lung Cancer in 2013: State of the Art Therapy for Metastatic Disease
Shepherd, F. A., Bunn, P. A., & Paz-Ares, L. G. (2013) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbook_am.2013.33.339 · Cited by 17
EGFR Mutations in US Hispanic Versus Non-Hispanic White Patients With Lung Adenocarcinoma
Zhang, W. J., McQuitty, E., Olsen, R. J., Fan, H., Hendrickson, H. L., Tio, F. O., Newton, K., Cagle, P. T., & Jagirdar, J. S. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0311-oa · Cited by 15
Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases
Stefanou, D. T., Stamatopoulou, S., Sakellaropoulou, A., Akakios, G., Gkiaouraki, M., Gkeka, D., Prevezanou, M., & Ardavanis, A. S. (2016) · Oncology Letters · doi:10.3892/ol.2016.5268 · Cited by 15
The Predictive Value of Early In-Treatment 18F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non–Small Cell Lung Cancer
Usmanij, E. A., Natroshvili, T., Timmer-Bonte, J. N. H., Oyen, W. J. G., van der Drift, M. A., Bussink, J., & de Geus‐Oei, L. (2017) · Journal of Nuclear Medicine · doi:10.2967/jnumed.116.185314 · Cited by 15
Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy
Zhang, R., Jia, M., Xue, H., Xu, Y., Wang, M., Zhu, M., Sun, M., Chang, J., & Wei, Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-10800-5 · Cited by 15
Specific Safety Profile of Bevacizumab in Asian Patients With Advanced NSCLC
Chen, Z., Zhong, B., Lun, X., Lai, Y., Bella, A. É., Yang, W., & Wu, J. (2015) · Medicine · doi:10.1097/md.0000000000000975 · Cited by 15
Randomized Phase III Trial of Docetaxel Plus Carboplatin with or without Levofloxacin Prophylaxis in Elderly Patients with Advanced Non-small Cell Lung Cancer: The APRONTA Trial
Schuette, W., Nagel, S., von Weikersthal, L. F., Pabst, S., Schumann, C., Deuß, B., Salm, T., Roscher, K., & Dickgreber, N. J. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3182307e3c · Cited by 15
Timing of chemotherapy-induced neutropenia is a prognostic factor in patients with metastatic non-small-cell lung cancer: a retrospective analysis in gemcitabine-plus-platinum-treated patients
Jang, S. H., Kim, S. Y., Kim, J., Park, S., Hwang, Y. I., Kim, D.-G., & Jung, K. (2012) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-012-1341-9 · Cited by 16
Recent Advancements of Monotherapy, Combination, and Sequential Treatment of EGFR/ALK-TKIs and ICIs in Non–Small Cell Lung Cancer
Liao, D., Yu, L., Shangguan, D., Zhang, Y., Xiao, B., Liu, G., & Yang, N. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905947 · Cited by 14
From Clinical Trials to Clinical Practice: Predictors of Response to Erlotinib in Advanced Non-Small Cell Lung Cancer Patients Pretreated with Chemotherapy
Mazzoni, F., Rotella, V., Pratesi, N., Boni, L., Simi, L., Orlando, C., Comin, C., Maddau, C., & Costanzo, F. D. (2011) · Tumori Journal · doi:10.1177/030089161109700205 · Cited by 14
Traitement de maintenance dans les cancers bronchiques non à petites cellules métastatiques : une révolution conceptuelle ?
Pérol, M., & Arpin, D. (2011) · La Presse Médicale · doi:10.1016/j.lpm.2011.01.009 · Cited by 13
NCCN Guidelines Version 1.2015 Panel Members Non-Small Cell Lung Cancer
Ettinger, D. S., Kimmel, S., Wood, D. E., Akerley, W., Bazhenova, L. A., Borghaei, H., Camidge, D. R., Cheney, R. T., Chirieac, L. R., Jahan, T. M., et al. (2014) · Cited by 14
First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients With Locally Advanced or Metastatic Nonsquamous Non–Small-cell Lung Cancer: Quality of Life Results From a Randomized Phase III Trial
Boye, M. E., Wang, X., Srimuninnimit, V., Kang, J. H., Tsai, C., Orlando, M., Puri, T., Kim, J. S., Rajan, N., & Yang, J. C. (2015) · Clinical Lung Cancer · doi:10.1016/j.cllc.2015.12.004 · Cited by 14
Role of Gemcitabine and Pemetrexed as Maintenance Therapy in Advanced NSCLC: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Hu, X., Pu, K., Feng, X., Wen, S., Fu, X. B., Guo, C., & He, W. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149247 · Cited by 14
Impact of Targeted Therapy on the Quality of End-of-Life Care for Patients With Non–Small-Cell Lung Cancer: A Population-Based Study in Taiwan
Tsai, H., Chung, K., & Kuo, R. N.-C. (2017) · Journal of Pain and Symptom Management · doi:10.1016/j.jpainsymman.2017.10.009 · Cited by 14
EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors
Liu, Y., Wang, H., Yang, S., Yang, Y., Wu, Y., He, Z., Ma, S., Mo, Y., Chen, H., Wang, Q., et al. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-755 · Cited by 14
Biomarkers in the management of lung cancer: changing the practice of thoracic oncology
Melichar, B. (2022) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2022-1108 · Cited by 15
Maintenance therapy with pemetrexed versus docetaxel after induction therapy with carboplatin and pemetrexed in chemotherapy-naïve patients with advanced non-squamous non-small-cell lung cancer: a randomized, phase II study
Karayama, M., Inui, N., Kuroishi, S., Yokomura, K., Toyoshima, M., Shirai, T., Masuda, M., Yamada, T., Yasuda, K., Suda, T., et al. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2218-6 · Cited by 14
Palliative Chemotherapy
Swetz, K. M., & Smith, T. J. (2010) · The Cancer Journal · doi:10.1097/ppo.0b013e3181f28ab3 · Cited by 14
Self-citation
A Phase II Study of Amrubicin as a Third-Line or Fourth-Line Chemotherapy for Patients With Non-Small Cell Lung Cancer: Hokkaido Lung Cancer Clinical Study Group Trial (HOT) 0901
Harada, T., Oizumi, S., Ito, K., Takamura, K., Kikuchi, E., Kuda, T., Sugawara, S., Suzuki, A. S., Maemondo, M., Fujita, Y., et al. (2013) · The Oncologist · doi:10.1634/theoncologist.2012-0308 · Cited by 14
Experience of first- and subsequent-line systemic therapy in the treatment of non-small cell lung cancer
Eccles, B., Geldart, T., Laurence, V., Bradley, K., & Lwin, M. T. (2011) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834011409096 · Cited by 14
Erlotinib for Pretreated Squamous Cell Carcinoma of the Lung in Japanese Patients
Hata, A., Katakami, N., Kunimasa, K., Yoshioka, H., Fujita, S., Kaji, R., Tachikawa, R., Tomii, K., Imai, Y., Iwasaku, M., et al. (2011) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyr159 · Cited by 14
Assessment of palliative care for advanced non-small-cell lung cancer in France: A prospective observational multicenter study (GFPC 0804 study)
Vergnenégre, A., Hominal, S., Tchalla, A. E., Berard, H., Monnet, I., Fraboulet, G., Baize, N., Audigier-Valette, C., Robinet, G., Oliviero, G., et al. (2013) · Lung Cancer · doi:10.1016/j.lungcan.2013.07.014 · Cited by 14
Novel biomarkers of metastatic cancer
Dawood, S. S. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.35 · Cited by 14
Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
Wang, Y., Wang, M., Wang, Q., Geng, Z., & Sun, M. (2017) · Oncotarget · doi:10.18632/oncotarget.14707 · Cited by 15
Semi-automatic volumetric measurement of response to chemotherapy in lung cancer patients: How wrong are we using RECIST?
Greenberg, V., Lazarev, I., Frank, Y., Dudnik, J., Ariad, S., & Shelef, I. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.02.017 · Cited by 14
Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative
Snee, M., Cheeseman, S., Thompson, M., Riaz, M., Sopwith, W., Lacoin, L., Chaib, C., Daumont, M., Penrod, J. R., O’Donnell, J. C., et al. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043442 · Cited by 14
IL-15/sIL-15Rα gene transfer suppresses Lewis lung cancer growth in the lungs, liver and kidneys
Sun, H., & Liu, D. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2015.67 · Cited by 14
Comparison of Metabolic and Anatomic Response to Chemotherapy Based on PERCIST and RECIST in Patients with Advanced Stage Non-small Cell Lung Cancer
Ordu, Ç., Selçuk, N. A., Akosman, C., Eren, O. Ö., Altunok, E. Ç., Toklu, T., & Oyan, B. (2015) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2015.16.1.321 · Cited by 13
Sequential addition of aprepitant in patients receiving carboplatin-based chemotherapy
Suzuki, S., Karayama, M., Inui, N., Kuroishi, S., Fujisawa, T., Enomoto, N., Nakamura, Y., Yokomura, K., Toyoshima, M., Imokawa, S., et al. (2016) · Medical Oncology · doi:10.1007/s12032-016-0780-6 · Cited by 13
Role of GSDM family members in airway epithelial cells of lung diseases: a systematic and comprehensive transcriptomic analysis
Liu, X., Zhang, L., Zhu, B., Liu, Y., Li, L., Hou, J., Qian, M., Zheng, N., Zeng, Y., Chen, C., et al. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09799-5 · Cited by 14
Cost comparison of second-line treatment options for late stage non-small-cell lung cancer: cost analysis for Italy
Schwander, B., Ravera, Giuliani, G., Nuijten, & Walzer, S. (2012) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s34371 · Cited by 13
Plasma epidermal growth factor receptor mutation analysis and possible clinical applications in pulmonary adenocarcinoma patients treated with erlotinib
Chen, Y.-M., Fan, W.-C., Tseng, P.-C., Tsai, C., Chou, T., Wu, C.-H., Chou, K., Lee, Y.-C., Perng, R.-P., & Whang‐Peng, J. (2011) · Oncology Letters · doi:10.3892/ol.2011.534 · Cited by 13
Non-platinum regimens of gemcitabine plus docetaxel versus platinum-based regimens in first-line treatment of advanced non-small cell lung cancer: a meta-analysis on 9 randomized controlled trials
Yu, Y., Xu, X., Du, Z., & Shi, M. (2012) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-012-1833-y · Cited by 13
A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)
Ikezawa, Y., Asahina, H., Oizumi, S., Watanabe, M., Takamura, K., Kawai, Y., Yamada, N., Harada, T., Kinoshita, I., Fujita, Y., et al. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3432-4 · Cited by 13
Improving Outcomes in Advanced Lung Cancer : Maintenance Therapy in Non-Small-Cell Lung Carcinoma = تحسين النتائج في سرطان الرئة المتقدم : العلاج المستدام في سرطان الرئة ذي الخلية غير الصغيرة
Furrukh, M., Burney, I. A., Kumar, S., Zahid, K. F., & Al-Moundhri, M. S. (2013) · Sultan Qaboos University medical journal · doi:10.12816/0003190 · Cited by 13
Erlotinib and Bevacizumab in Newly Diagnosed Performance Status 2 or Elderly Patients With Nonsquamous Non–Small-Cell Lung Cancer, a Phase II Study of the Hoosier Oncology Group: LUN04-77
Riggs, H., Jalal, S. I., Baghdadi, T. A., Bhatia, S., McClean, J., Johnson, C. S., Yu, M., Taber, D. A., Harb, W. A., & Hanna, N. H. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.09.004 · Cited by 13
An Economic Model to Value Companion Diagnostics in Non-Small-Cell Lung Cancer
Lieberthal, R. D., Dudash, K., Axelrod, R. S., & Goldfarb, N. I. (2013) · Personalized Medicine · doi:10.2217/pme.13.7 · Cited by 13
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Yonesaka, K., Suzumura, T., Tsukuda, H., Hasegawa, Y., Ozaki, T., Sugiura, T., & Fukuoka, M. (2014) · PubMed · Cited by 13
Variations in Oncologist Recommendations for Chemotherapy for Stage IV Lung Cancer: What Is the Role of Performance Status?
Tisnado, D. M., Malin, J. K., Kahn, K. L., Landrum, M. B., Fletcher, R. H., Klabunde, C. N., Clauser, S. B., Rogers, S. O., & Keating, N. L. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2015.008425 · Cited by 13

Authors: Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., Nordquist, L., Pfister, D. G., Piantadosi, S., Schiller, J. H., Smith, R., Smith, T. J., Strawn, J. R., Trent, D., & Giaccone, G.
Affiliations: American Society of Clinical Oncology (US)
ORCID: Azzoli, Christopher G.
Temin, Sarah
Pao, William
Brahmer, Julie
Johnson, David H.
Masters, Gregory
Pfister, David G.
Piantadosi, Steven
Schiller, Joan H.
Smith, Thomas J.
Giaccone, Giuseppe
Venue: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Published: 2009-12-20
Volume: 27
Issue: 36
Pages: 6251-6266
ISSN: 0732-183X (ISSN-L)
1527-7755
DOI: 10.1200/jco.2009.23.5622
PMC: PMC2793036
OpenAlex: W2119366998
Cited by: 915
References: 218
Citations by year: 2026: 6 · 2025: 4 · 2024: 9 · 2023: 8 · 2022: 12 · 2021: 25 · 2020: 21 · 2019: 33 · 2018: 38 · 2017: 38 · 2016: 67 · 2015: 89 · 2014: 111 · 2013: 128 · 2012: 119
FWCI: 90.05
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Journal of Clinical Oncology (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: stage IV non-small cell lung cancer, chemotherapy, first-line therapy, second-line therapy, third-line therapy, gefitinib, erlotinib, bevacizumab, carboplatin-paclitaxel, cetuximab, docetaxel, EGFR mutation, platinum-based doublets, overall survival, progression-free survival, treatment toxicity
MeSH terms: Carcinoma, Non-Small-Cell Lung, Humans, Lung Neoplasms, Neoplasm Staging

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non–Small-Cell Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks